Spots Global Cancer Trial Database for myeloma multiple
Every month we try and update this database with for myeloma multiple cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bioequivalence Studies of Dasatinib 100 mg | NCT05944783 | Myeloma Multipl... | Dasatinib 100 M... | 18 Years - 50 Years | Centro de Atencion e Investigacion Medica | |
| Corneal Toxicity in Patients Treated by Belantamab Mafodotin | NCT05887206 | Myeloma Multipl... | Collection of d... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study | NCT06418750 | Myeloma Multipl... | dermo-cosmetic ... | 18 Years - 100 Years | Nantes University Hospital | |
| CTFEA Myeloma Study | NCT04364724 | Myeloma Multipl... Metastatic Bone... | CT-based finite... | 18 Years - 95 Years | Tel-Aviv Sourasky Medical Center | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients | NCT06133426 | Lymphoma, Non-H... Myeloma Multipl... | Connected scale... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | NCT03607643 | Cancer of Pancr... Cancer of Liver Cancer of Rectu... Cancer of Colon Cancer, Gall Bl... Myeloma Multipl... Glioblastoma Mu... | Cannabidiol Bortezomib Leucovorin 5-FU Oxaliplatin Bevacizumab Irinotecan Gemcitabine Temozolomide | 18 Years - 80 Years | Leaf Vertical Inc. | |
| Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | NCT03191981 | Myeloma Multipl... | Cyclophosphamid... Lenalidomide Pembrolizumab | 18 Years - 99 Years | University of Leeds | |
| Limited-duration Teclistamab | NCT05932680 | Myeloma Multipl... | Off Drug Survei... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | NCT04843579 | Myeloma Multipl... Myeloma Refractory Mult... | Selinexor Clarithromycin Pomalidomide Dexamethasone | 18 Years - 74 Years | Weill Medical College of Cornell University | |
| Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant | NCT05338047 | Myeloma Multipl... Lymphoma | Pegfilgrastim | 18 Years - 90 Years | Hospital Universitario Dr. Jose E. Gonzalez | |
| Corneal Toxicity in Patients Treated by Belantamab Mafodotin | NCT05887206 | Myeloma Multipl... | Collection of d... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM | NCT06205823 | Myeloma Multipl... | Immunotherapy | 19 Years - | Seoul St. Mary's Hospital | |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | NCT04816526 | Myeloma Multipl... | Descartes 08 | 18 Years - | Cartesian Therapeutics | |
| Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | NCT06245629 | Myeloma Multipl... | Bortezomib-bend... | 18 Years - | Uppsala University | |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | NCT04436029 | Myeloma Multipl... | Descartes 11 | 18 Years - | Cartesian Therapeutics | |
| Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients | NCT04843579 | Myeloma Multipl... Myeloma Refractory Mult... | Selinexor Clarithromycin Pomalidomide Dexamethasone | 18 Years - 74 Years | Weill Medical College of Cornell University | |
| Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | NCT05091372 | Myeloma Multipl... | Belantamab mafo... Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| CTFEA Myeloma Study | NCT04364724 | Myeloma Multipl... Metastatic Bone... | CT-based finite... | 18 Years - 95 Years | Tel-Aviv Sourasky Medical Center | |
| Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM | NCT06205823 | Myeloma Multipl... | Immunotherapy | 19 Years - | Seoul St. Mary's Hospital | |
| Limited-duration Teclistamab | NCT05932680 | Myeloma Multipl... | Off Drug Survei... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Effect of Vitamin C in Autologous Stem Cell Transplantations | NCT03964688 | Myeloma Multipl... Lymphoma | Vitamin C Placebos | 18 Years - | Maastricht University Medical Center | |
| Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma | NCT06245629 | Myeloma Multipl... | Bortezomib-bend... | 18 Years - | Uppsala University | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Bioequivalence Studies of Dasatinib 100 mg | NCT05944783 | Myeloma Multipl... | Dasatinib 100 M... | 18 Years - 50 Years | Centro de Atencion e Investigacion Medica | |
| Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | NCT04816526 | Myeloma Multipl... | Descartes 08 | 18 Years - | Cartesian Therapeutics | |
| Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive | NCT03992170 | Myeloma Multipl... | Daratumumab | 18 Years - 85 Years | Azienda Ospedaliera Universitaria Senese | |
| Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive | NCT03992170 | Myeloma Multipl... | Daratumumab | 18 Years - 85 Years | Azienda Ospedaliera Universitaria Senese | |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors | NCT04236063 | Haematological ... Leukemia, Acute Lymphoma Myeloma Multipl... Blood Cancer Quality of Life | WHODAS 2.0 Ques... | 18 Years - 80 Years | University of Malaya | |
| Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden | NCT04760184 | Covid19 Myeloma Multipl... Malignant Lymph... Hematologic Neo... Stem Cell Trans... | Autologous stem... | 18 Years - | Uppsala University | |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors | NCT04236063 | Haematological ... Leukemia, Acute Lymphoma Myeloma Multipl... Blood Cancer Quality of Life | WHODAS 2.0 Ques... | 18 Years - 80 Years | University of Malaya | |
| A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment | NCT04268199 | Myeloma Myeloma Multipl... | Bortezomib Inje... | 18 Years - | AHS Cancer Control Alberta | |
| The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood | NCT04242121 | Myeloma Multipl... | fluorescence fl... | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT04394650 | Multiple Myelom... | CC-98633 | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study | NCT06418750 | Myeloma Multipl... | dermo-cosmetic ... | 18 Years - 100 Years | Nantes University Hospital | |
| Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | NCT04436029 | Myeloma Multipl... | Descartes 11 | 18 Years - | Cartesian Therapeutics | |
| Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma | NCT05889221 | Multiple Myelom... Myeloma Multipl... Myeloma | Drug and medica... | 65 Years - | Poitiers University Hospital | |
| A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | NCT03607643 | Cancer of Pancr... Cancer of Liver Cancer of Rectu... Cancer of Colon Cancer, Gall Bl... Myeloma Multipl... Glioblastoma Mu... | Cannabidiol Bortezomib Leucovorin 5-FU Oxaliplatin Bevacizumab Irinotecan Gemcitabine Temozolomide | 18 Years - 80 Years | Leaf Vertical Inc. | |
| Collection of Additional Data Followed the Study IFM 2013-04 | NCT03089411 | Myeloma Multipl... | 18 Years - 66 Years | Nantes University Hospital | ||
| Collection of Additional Data Followed the Study IFM 2013-04 | NCT03089411 | Myeloma Multipl... | 18 Years - 66 Years | Nantes University Hospital | ||
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | NCT05651932 | Multiple Myelom... Myeloma Myeloma Multipl... | KTX-1001 | 18 Years - | K36 Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
